Most Popular Stories
- Walgreens plans 100 more retail clinics by mid-2009
- Disruptive doctor behavior causes mistakes, intimidates workers
- AHA survey: Negative profit margins for hospitals
- DOD, VA move to SOA architecture to build interoperable systems
- HHS: 60 percent of DME companies banned by Medicare may keep billing
- Cleveland Clinic lists potential conflicts of interest online
Poll
Featured Jobs
-
CA Nursing Direct. Medical/Telemetry
StaffPointe, LLC - San Francisco , CA -
Michigan Internist SLB1196tsNET
StaffPointe, LLC - northern , MI -
Nevada Internal Medicine
StaffPointe, LLC - Las Vegas , NV -
Arizona Nurse Practitioner
StaffPointe, LLC - southwest , AZ -
Florida OB/GYN
StaffPointe, LLC - west , FL
Events
- Avaya Patient Payment Recovery Webinar
Thursday, December 11, 2008 1-2pm
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
- Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
Popular Topics
Emory psychiatrist accused of not reporting drug company income
A high-profile Emory University psychiatrist has been accused of failing to report one-third of the $2.8 million in consulting fees he received from companies whose drugs he was evaluating, according to Congressional investigators. The psychiatrist, Dr. Charles Nemeroff, got the money from GlaxoSmithKline between 2000 and 2007, while he was principal investigator on a $3.9 million NIH study of five Glaxo drugs used for treatment of depression, investigators said. Nemeroff is the sixth psychiatrist named as facing similar conflicts of interest since the Congressional probe began.
According to Congressional researchers, Dr. Nemeroff continued to get large amounts of money for giving speeches to other doctors, despite having signed University documents pledging to accept no more than $10,000 a year from any one company. Since the allegations were revealed, Nemeroff has stepped down as chairman of Emory's psychiatry department.
The ongoing investigation of such conflicts of interest is being spearheaded by Sen. Charles Grassley (R-IA), who is promoting a bill that would require pharmaceutical and medical device companies to disclose all payments over $500 they make to physicians.
To learn more about these allegations, and the ongoing investigation:
- read this Los Angeles Times piece
Related Articles:
Harvard psychiatrists fail to reveal millions in pharma pay
Psychiatrists getting the largest pharma gifts
Bill would make pharmas, device makers disclose gifts
Related Stories
- Drug companies plan to disclose grant funding
- ALSO NOTED: U of Miami suffers massive patient data loss; Loyola U sets $1B strategic plan; and much more...
- Psych journal discloses financial ties to industry
- Glaxo to report grants to U.S. healthcare groups
- Did Glaxo conceal Paxil users' risk of suicide?
- Non-profit hospital tax breaks attacked by Grassley, again
- Addiction is a worse scourge for some
- More objections to Avandia suppressed by Glaxo
- Using the MRI to map mental states
- Health reporters can have conflicts of interest, too
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





